National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

serine/threonine kinase inhibitor XL418
A selective, orally active small molecule, targeting protein kinase B (PKB or AKT) and ribosomal protein S6 Kinase (p70S6K), with potential antineoplastic activity. XL418 inhibits the activities of PKB and p70S6K, both acting downstream of phosphoinosotide-3 kinase (PI3K). These kinases are often upregulated in a variety of cancers. Inhibition of PKB by this agent will induce apoptosis, while inhibition of p70S6K will result in the inhibition of translation within tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:XL418



Previous:Seneca Valley virus-001, senna extract, Sensorcaine-MPF, Septra, serine protease inhibitor WX-671
Next:Seromycin, Serophene, sertraline hydrochloride, sevoflurane, shark cartilage

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov